Keynote-966 trial in progress: pembrolizumab added to gemcitabine and cisplatin for advanced biliary tract cancer
Kelley, R. K. Vogel, A. Furuse, J. Edeline, J. Finn, R. Ren, Z. G. Su, S. C. Malhotra, U. Siegel, A. B. Valle, Juan W
Kelley, R. K.
Vogel, A.
Furuse, J.
Edeline, J.
Finn, R.
Ren, Z. G.
Su, S. C.
Malhotra, U.
Siegel, A. B.
Valle, Juan W
Citations
Altmetric:
Abstract
Background: Biliary tract cancer (BTC), comprising intra- and extra-hepatic cholangiocarcinoma
and gallbladder cancer, is a rare and aggressive malignancy. Most patients (pts) present with advanced or unresectable disease, for which the current
standard of care is gemcitabine plus cisplatin. Median survival for these pts is only 12 inhibitor that has demonstrated modest antitumor activity as monotherapy in pts
with previously treated BTC and has improved survival when used in combination with platinum-based chemotherapy in other cancer types.
months, highlighting the need for more effective therapies. Pembrolizumab is a PD-1 inhibitor that has demonstrated modest antitumor activity as monotherapy in pts
with previously treated BTC and has improved survival when used in combination
with platinum-based chemotherapy in other cancer types.
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Kelley RK, Vogel A, Furuse J, Edeline J, Finn R, Ren ZG, et al. Keynote-966 trial in progress: pembrolizumab added to gemcitabine and cisplatin for advanced biliary tract cancer. Hepatology. 2020;72:697A-A.